Kailera Therapeutics shares jump 62.5% in Nasdaq debut
Weight-loss drug developer Kailera Therapeutics' shares surged 62.5% in their Nasdaq debut on Friday after closing a $625 million U.S. initial public offering, as Wall Street's appetite for the fast-growing market remains unsated. Kailera had…